SecBot SecBot
Biotech Drug Report Generated Jun 30, 2026

KRESLADI

RCKT·ROCKET PHARMACEUTICALS, INC.
NEUTRAL
Drug Impact Rating4/10
Trial phase
Approved (FDA accelerated approval)
Time to market
Already FDA-approved (March 26, 2026); commercial launch underway
Why 4/10
KRESLADI is already FDA-approved (March 26, 2026) with no pending regulatory decision. The defining binary catalyst has passed. The stock's next hard catalysts are related to Rocket's pipeline (RP-A501 Danon disease data, RP-A701 BAG3 cardiomyopathy dosing), not KRESLADI itself.
Actionable Insight NEUTRAL

KRESLADI's approval and the $180M PRV sale provide a cash runway into Q2 2028, but the drug is an ultra-orphan gene therapy with a "minimal viable launch", not a major revenue generator. Watch the company's cardiovascular pipeline (RP-A501 for Danon disease, RP-A701 for BAG3 cardiomyopathy) for future catalysts. RCKT carries heavy short interest (~25.5% of float), a squeeze risk if pipeline data hits, but the clinical hold history on RP-A501 adds risk.

Price Chart

Loading chart...

Executive Summary

KRESLADI (marnetegragene autotemcel) is Rocket Pharmaceuticals' first FDA-approved product, a one-time gene therapy for severe leukocyte adhesion deficiency type I (LAD-I), an ultra-rare pediatric immune disorder. It was approved via accelerated approval on March 26, 2026, after a Phase 1/2 trial showed 100% survival. The company then sold its rare pediatric disease Priority Review Voucher for $180M in April 2026, extending its cash runway. However, with an ultra-orphan patient population (~1 in 1M), Rocket plans only a 'minimal viable launch,' and the stock has declined ~27% since approval to ~$3.45, weighed by clinical holds on the key pipeline drug RP-A501. The defining binary for KRESLADI has passed; future value depends on pipeline execution.

How It Works

KRESLADI is a one-time gene therapy made from the patient's own blood stem cells. The cells are collected, genetically modified in a lab to carry a working copy of a crucial gene (ITGB2), and infused back into the patient. This enables their white blood cells to produce a protein called CD18, which is essential for immune cells to leave the bloodstream and reach infection sites. Without it, children suffer fatal, recurrent infections.

Trial Status

Approved under FDA accelerated approval based on a global Phase 1/2 study that demonstrated 100% overall survival at 12 months post-infusion and beyond for all 9 enrolled patients. All primary and secondary endpoints were met. A confirmatory study is ongoing to verify clinical benefit.

The Two-Sided Case

▲ Bull Case5
KRESLADI is the first and only FDA-approved gene therapy for severe LAD-I, a true breakthrough for an ultra-rare, fatal pediatric disease with no adequate treatment alternative for patients without a matched bone marrow donor.
The $180M sale of the rare pediatric disease PRV (closed June 12, 2026) provides substantial non-dilutive capital, extending Rocket's cash runway into Q2 2028 and de-risking the company's near-term financing needs.
The Phase 1/2 data showed 100% overall survival for all treated patients with no treatment-related serious adverse events, a compelling efficacy/safety profile for a fatal disease where the alternative (allogeneic transplant) carries significant mortality risk.
RCKT trades at ~$3.45 with a consensus analyst price target of ~$9.39 (186.5% upside implied) despite the approval being already priced in, the market may be undervaluing the pipeline upside.
Short interest is elevated at ~25.5% of float with 8.4 days to cover, creating squeeze potential if positive pipeline catalysts emerge.
▼ Bear Case5
KRESLADI is an ultra-orphan drug, the CEO described it as a 'minimal viable launch' with annual treated patients expected to remain very low. It will not be a meaningful revenue driver regardless of approval.
The stock dropped ~20% on the day of FDA approval (March 27, 2026), suggesting the market either expected more or is focused on pipeline risks at the company.
Rocket's other key pipeline asset, RP-A501 for Danon disease, has experienced serious clinical holds, one in May 2025 (patient death) and another noted in May 2026, creating significant binary risk for the stock's overall thesis.
The accelerated approval requires a confirmatory study to verify clinical benefit, if that study fails to confirm, the FDA could withdraw the indication.
Goldman Sachs maintains a Sell rating on RCKT, and the analyst consensus is split (4 strong buy / 7 buy / 7 hold / 2 sell), no clear conviction.

Upcoming Catalysts

  • RP-A501 Phase 2 pivotal trial data for Danon disease (next major pipeline catalyst)
  • First patient dosing in Phase 1 study of RP-A701 for BAG3-related dilated cardiomyopathy (mid-2026)
  • KRESLADI confirmatory study data readouts (ongoing, no hard date set)
  • Quarterly earnings reports, KRESLADI launch metrics and commercial traction

Source Filing

The SEC filing that triggered this drug report:

ROCKET PHARMACEUTICALS, INC. SEC filing RCKT ·Accession 0001140361-26-006981

Sources · 13

Hover a chip for the title
1 businesswire.com2 fda.gov3 fda.gov4 ir.rocketpharma.com5 fiercepharma.com6 fiercepharma.com7 en.wikipedia.org8 ir.rocketpharma.com9 ir.rocketpharma.com10 marketbeat.com11 cgtlive.com12 statnews.com13 ir.rocketpharma.com